Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-cash Items (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Non-cash Items for 8 consecutive years, with $426000.0 as the latest value for Q1 2025.

  • Quarterly Non-cash Items fell 59.83% to $426000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $426000.0 through Mar 2025, down 59.83% year-over-year, with the annual reading at $4.2 million for FY2023, 5.61% down from the prior year.
  • Non-cash Items for Q1 2025 was $426000.0 at Crescent Biopharma, down from $8.8 million in the prior quarter.
  • The five-year high for Non-cash Items was $8.8 million in Q3 2024, with the low at $1500.0 in Q1 2021.
  • Average Non-cash Items over 5 years is $2.8 million, with a median of $2.6 million recorded in 2021.
  • Peak annual rise in Non-cash Items hit 39443.24% in 2021, while the deepest fall reached 99.95% in 2021.
  • Over 5 years, Non-cash Items stood at $4.9 million in 2021, then dropped by 9.86% to $4.4 million in 2022, then fell by 5.61% to $4.2 million in 2023, then surged by 110.25% to $8.8 million in 2024, then plummeted by 95.18% to $426000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $426000.0, $8.8 million, and $1.2 million for Q1 2025, Q3 2024, and Q2 2024 respectively.